Is Vaxcyte, Inc. (PCVX) a Buy, Sell, or Hold?
Vaxcyte, Inc.
NASDAQ:PCVX
$56.74 USD
$0.53 (0.94%)
- Volume
- 763.08K
- Average Volume
- 1.62M
- Market Capitalization
- $8.19B
- P/E Ratio
- -8.24
- Dividend Yield
- 0.00%
- Price Target
- $89.00
- Year High
- $65.00
- Year Low
- $29.08
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.49
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Grant E. Pickering |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | PCVX |
| CUSIP | 92243G108 |
| CIK | 0001649094 |
| Web | https://vaxcyte.com |
| Phone | 650 837 0111 |
| Currency | USD |
| Employees | 507 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.04 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.49 |
| Quick Ratio | 7.49 |
| Cash Ratio | 1.08 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -5.53 |
| Price / Cash Flow | -10.62 |
| Price / Book | 2.64 |
Price Target and Rating
| Average Stock Price Forecast | $89.00 |
| High Stock Price Forecast | $89.00 |
| Low Stock Price Forecast | $89.00 |
| Forecast Upside/Downside | -36.25% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-5.63 |
| Trailing P/E Ratio | -8.24 |
| PEG Ratio | 0.18 |
| P/E Growth | 0.18 |
| Net Income | $-766.63M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -32.51% |
| Return on Assets | -28.27% |
Financials Score
| AltmanZ Score | 12.42 |
| Piotroski Score | 1.00 |
| Working Capital | 1.57B |
| Total Assets | 3.35B |
| Ebit | -946.53M |
| Market Cap | 8.12B |
| Total Liabilities | 352.29M |
Poll Results
About Vaxcyte, Inc. (NASDAQ:PCVX) Stock
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsi ... ble for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Vaxcyte to Participate in Upcoming Investor Conferences
2026-07-08 16:05:00
SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences:
2026-06-02 16:05:00
First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus
Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
2026-05-12 19:10:45
Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-06 16:05:00
Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market
2026-05-01 22:59:00
Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced manufacturing and regulatory alignment. VAX-31, a 31-valent pneumococcal conjugate vaccine, targets broader serotype coverage than competitors and is in pivotal Phase 3 adult and Phase 2 infant trials. PCVX boasts strong financials, with over $2.4B in cash and a completed manufacturing facility, enabling concurrent late-stage development and commercial preparation.
Frequently Asked Questions
-
What is the current Vaxcyte, Inc. (PCVX) stock price?
-
Vaxcyte, Inc.(NASDAQ:PCVX) stock price is $56.74 in the last trading session. During the trading session, PCVX stock reached the peak price of $65 while $29.08 was the lowest point it dropped to. The percentage change in PCVX stock occurred in the recent session was 0.94% while the dollar amount for the price change in PCVX stock was $0.53.
-
PCVX's industry and sector of operation?
-
The NASDAQ listed PCVX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PCVX?
-
Whitney Jones | Chief People Officer
Elvia Cowan | Senior VP of Finance & Chief Accounting Officer
Mikhail Eydelman | Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary
Janet Graesser | Senior Vice President of Corporate Affairs
Grant E. Pickering | Co-Founder, Chief Executive Officer & Director -
How many employees does PCVX have?
-
Number of PCVX employees currently stands at 507. PCVX operates from 825 Industrial Road, San Carlos, CA 94070, US.
-
Link for PCVX official website?
-
Official Website of PCVX is: https://vaxcyte.com
-
How do I contact PCVX?
-
PCVX could be contacted at phone #650 837 0111 and can also be accessed through its website. PCVX operates from 825 Industrial Road, San Carlos, CA 94070, US.
-
How many shares of PCVX are traded daily?
-
The average number of PCVX shares traded daily for last 3 months was 1.62M.
-
What is the market cap of PCVX currently?
-
The market value of PCVX currently stands at $8.19B with its latest stock price at $56.74